In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Use of oral anticoagulants in AF patients undergoing cardioversion

EHRA webinar

07/12/2017 18:00 07/12/2017 19:00 Europe/Paris Use of oral anticoagulants in AF patients undergoing cardioversion

Access event page

European Heart Rhythm Association DD/MM/YYYY
Arrhythmias, General
Atrial Fibrillation

Focus on

Learning Objectives:

  • To understand when and how a patient treated long-term with a NOAC can be safely cardioverted
  • How to initiate NOAC Therapy in an OAC naïve patient who needs cardioversion
  • What is the role of TEE in a NOAC treated person undergoing cardioversion

Watch the webinar recording




hein-heidbuchel.jpgProfessor Hein Heidbuchel, FEHRA
University Hospital Antwerp
Antwerp, Belgium


potpara-tatjana-2017 (2).jpgProfessor Tatjana Potpara, FESC
Internal Medicine/Cardiology, School of Medicine
University of Belgrade
Belgrade, Serbia



hohnloser_stefan h-2015.jpgProfessor Stefan Hohnloser, FESC
Medizinische Klinik IV
Kardiologie Klinikum der J.-W.-Goethe-Universitat
Frankfurt, Germany


Session information

This webinar is addressed to EHRA members and cardiologists working in the field of arrhythmias.

During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide feedback live.

An application has been made to the EACCME® for CME accreditation of this event.

Technical settings

The webinar is available on PC and Tablets. The use of a smartphone is not recommended.  

To answer the MCQs during the live, you must allow pop-up windows.

A high-speed Internet connection is required (minimum 2 Mbps).


This programme is supported by BMS/Pfizer in the form of an educational grant.

The scientific programme has not been influenced in any way by its sponsor.